Behaviours such as eating, copulating, defending oneself or taking addictive drugs begin
with a motivation to initiate the behaviour. Both this motivational drive and the behaviours …

Drug, alcohol and tobacco use disorders are a global burden affecting millions of people.
Despite decades of research, treatment options are sparse or missing, and relapse rates are …

Background Alcohol use disorder (AUD) is a chronic, relapsing brain disorder that accounts
for 5% of deaths annually, and there is an urgent need to develop new targets for …

Background Glucagon-like peptide1 receptor (GLP-1R) agonists have been found to reduce
alcohol drinking in rodents and overweight patients with alcohol use disorder (AUD) …

Glucagon-like peptide-1 (GLP-1) is a human incretin hormone derived from the proglucagon
molecule. GLP-1 receptor agonists are frequently used to treat type 2 diabetes mellitus and …

Abstract Alcohol Use Disorder (AUD) contributes significantly to global mortality. GLP-1
(Glucagon-like peptide-1) and GLP-1/GIP (Glucose-dependent Insulinotropic Polypeptide) …

Objective Glucagon-like peptide-1 receptor (GLP-1R) agonists (GLP-1RA) and fibroblast
growth factor-21 (FGF21) confer similar metabolic benefits. GLP-1RA induce FGF21, leading …

Although the multifaceted mechanisms underlying alcohol use disorder (AUD) have been
partially defined, the neurobiological complexity of this disorder is yet to be unraveled. One …

Dysfunctional signaling in midbrain reward circuits perpetuates diseases characterized by
compulsive overconsumption of rewarding substances such as substance abuse, binge …

The role of glucagon-like peptide 1 (GLP-1) in insulin-dependent signaling is well-known;
GLP-1 enhances glucose-dependent insulin secretion and lowers blood glucose in …